Quantinno Capital Management LP Cuts Stock Position in Humana Inc. $HUM

Key Points

• Quantinno Capital Management cut its Humana position by 61.1% in the first quarter, selling 46,433 shares and retaining 29,585 shares valued at approximately $5.13 million. Institutional investors collectively own 92.38% of Humana’s stock.
• Humana exceeded quarterly expectations, reporting $7.61 in EPS versus the $7.27 consensus and $40.89 billion in revenue, up 26.2% year over year.
• Analyst sentiment remains positive, with Humana receiving a “Moderate Buy” consensus rating and an average price target of $391.87; recent upgrades included Wolfe Research, UBS Group and Leerink Partners.

Quantinno Capital Management LP cut its position in Humana Inc. (NYSE:HUM - Free Report) by 61.1% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 29,585 shares of the insurance provider's stock after selling 46,433 shares during the quarter. Quantinno Capital Management LP's holdings in Humana were worth $5,130,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Montag A & Associates Inc. raised its stake in shares of Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider's stock worth $25,000 after acquiring an additional 94 shares in the last quarter. Fideuram Asset Management Ireland dac acquired a new stake in Humana in the fourth quarter valued at approximately $27,000. Reflection Asset Management purchased a new position in Humana in the fourth quarter worth $29,000. Larson Financial Group LLC grew its holdings in Humana by 114.1% in the third quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider's stock worth $40,000 after purchasing an additional 81 shares during the last quarter. Finally, Fulcrum Asset Management LLP acquired a new position in shares of Humana during the third quarter worth $42,000. 92.38% of the stock is currently owned by institutional investors.

Humana Price Performance

NYSE HUM opened at $367.98 on Friday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.74 and a quick ratio of 1.74. The stock's fifty day moving average price is $375.61 and its 200 day moving average price is $270.85. Humana Inc. has a 1 year low of $163.11 and a 1 year high of $428.88. The company has a market cap of $44.19 billion, a price-to-earnings ratio of 34.81, a PEG ratio of 2.08 and a beta of 0.72.

Humana (NYSE:HUM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 29th. The insurance provider reported $7.61 EPS for the quarter, topping analysts' consensus estimates of $7.27 by $0.34. The company had revenue of $40.89 billion during the quarter, compared to analysts' expectations of $40.58 billion. Humana had a return on equity of 11.20% and a net margin of 0.88%.The firm's revenue was up 26.2% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.27 EPS. As a group, equities research analysts forecast that Humana Inc. will post 9.08 earnings per share for the current year.

Analysts Set New Price Targets

Several analysts have recently commented on HUM shares. Wolfe Research upgraded Humana from a "peer perform" rating to an "outperform" rating in a report on Thursday, July 30th. Weiss Ratings lowered Humana from a "hold (c)" rating to a "hold (c-)" rating in a research report on Thursday, July 30th. UBS Group began coverage on Humana in a research note on Thursday, July 30th. They issued a "buy" rating for the company. Sanford C. Bernstein reissued an "outperform" rating and issued a $425.00 price target on shares of Humana in a report on Wednesday, June 3rd. Finally, Leerink Partners upgraded Humana from a "market perform" rating to an "outperform" rating and set a $513.00 price target on the stock in a research note on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, fourteen have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $391.87.

About Humana

Humana Inc NYSE: HUM is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana's products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source